Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation-Reference-Cited by-同舟云学术

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

Published:2014-06-05 Issue:23 Volume:123 Page:3655-3663
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Pulsipher Michael A.¹,Chitphakdithai Pintip²,Logan Brent R.³,Navarro Willis H.²⁴,Levine John E.⁵,Miller John P.⁴,Shaw Bronwen E.⁶,O’Donnell Paul V.⁷,Majhail Navneet S.²⁸,Confer Dennis L.²⁴

Affiliation:

1. University of Utah School of Medicine, Primary Children’s Hospital, Salt Lake City, UT;

2. Center for International Blood and Marrow Transplant Research, Minneapolis, MN;

3. Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;

4. National Marrow Donor Program, Minneapolis, MN;

5. The University of Michigan, Ann Arbor, MI;

6. Anthony Nolan Research Institute, London, United Kingdom;

7. Fred Hutchinson Cancer Research Center, Seattle, WA; and

8. Cleveland Clinic, Cleveland, OH

Abstract

Key Points BM donors have a threefold higher risk for life-threatening, serious unexpected, or chronic adverse events vs PBSC donors (0.99% vs 0.31%). Donors receiving granulocyte colony-stimulating factor for PBSC collection had no evidence of increased risk for cancer, autoimmune illness, and stroke.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/23/3655/1377888/3655.pdf

Reference30 articles.

1. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program.;Miller;Biol Blood Marrow Transplant,2008

2. Unrelated hematopoietic stem cell donors as research subjects.;King;Bone Marrow Transplant,2011

3. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations.;Shaw;Bone Marrow Transplant,2010

4. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.;Pulsipher;Blood,2013

5. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor.;Parkkali;Bone Marrow Transplant,1996

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of cardiovascular disease in healthy Swedish peripheral blood stem cell donors – a nationwide study;Bone Marrow Transplantation;2024-01-11

2. Dental Pulp Stem Cells for Bone Tissue Engineering: A Literature Review;Stem Cells International;2023-10-11

3. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias;Blood Advances;2023-09-26

4. Small volume bone marrow aspirates with high progenitor cell concentrations maximize cell therapy dose manufacture and substantially reduce donor hemoglobin loss;BMC Medicine;2023-09-19

5. Adverse events related to central venous catheters (CVC) and the influence of CVC characteristics on peripheral blood hematopoietic progenitor cell collection in children;Frontiers in Pediatrics;2023-04-21